Drug
Didanosine clinical trials
- studies test it
- 62
- open now
- 0
- in phase 3
- 14
- first study started
- 1990
How studies write it
Studies that test it under each name
Name
- ddI
- 4
Combined with it in one product
Studies by the year they started
24 studies that test it; most in 1999 (5)
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1997 | 2 |
| 1999 | 5 |
| 2000 | 2 |
| 2001 | 1 |
| 2004 | 4 |
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 23
- Phase 3
- 14
- Phase 4
- 5
- No phase
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 38
National Institute of Allergy and Infectious Diseases (NIAID) (25) · Bristol-Myers Squibb (12) · National Cancer Institute (NCI) (2) · Triangle Pharmaceuticals (2) · Pharmacia and Upjohn (2) · AJI Pharma USA (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · ANRS, Emerging Infectious Diseases (1)
Often tested with
Tested in the same studies.
Zidovudine (19) · Stavudine (18) · Efavirenz (13) · Lamivudine (10) · Hydroxyurea (9) · Nevirapine (7) · Emtricitabine (5) · Delavirdine (4)
Studies
Open first, then newest update. How each study uses Didanosine is read from its arms, and is right about nine times in ten.
Testing it · 62
- Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00074581Written as Didanosine
- Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV DrugsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00016718Written as Didanosine (ddI)
- A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related ComplexCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000710Written as Didanosine
- A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected PatientsCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00001022Written as Didanosine
- A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination TherapyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000803Written as Didanosine
- A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000742Written as Didanosine
- A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and DidanosineCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000770Written as Didanosine
- Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected ChildrenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000851Written as Didanosine
- Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the DiseaseCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001045Written as Didanosine
- Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or DidanosineCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000838Written as Didanosine
- Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia ComplexCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000657Written as Didanosine
- A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV DiseaseCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000656Written as Didanosine
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00102960Written as Didanosine
- The Effectiveness of Two Anti-HIV Treatments in HIV-Infected PatientsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001057Written as Didanosine
- The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's SarcomaCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00001114Written as Didanosine
- A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIVCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00001049Written as Didanosine
- Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00008866Written as Didanosine
- A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take ZidovudineCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000963Written as Didanosine
- A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant WomenCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000839Written as Didanosine
- A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive IndividualsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000772Written as Didanosine
See all 62 studies that test Didanosine →
Given in every arm · 2 — Didanosine is usual care beside what is tested
- Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIVWithdrawnNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00051090Written as Didanosine
- Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TCCompletedPhase 3Hospital de GranollersNCT00338390Written as Didanosine
Codes
What other systems call Didanosine · ClinicalTrials.gg INT008512
- MeSH (NLM) D016049DidanosineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K3GDH6OH08DIDANOSINEConfirmed FDA, NLM, Wikidata
- RxNorm 3364Confirmed FDA, Wikidata
- Wikidata Q422606didanosineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C431DidanosineOne source FDA
- DrugBank DB00900One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D016049 | Didanosine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K3GDH6OH08 | DIDANOSINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 3364 | — | Confirmed FDA, Wikidata |
| Wikidata | Q422606 | didanosine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C431 | Didanosine | One source FDA |
| DrugBank | DB00900 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.